NCT01018680已完成3 期
A Randomized, Placebo-Controlled Trial of Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients With Knee Pain Due to Osteoarthritis Who Have Had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 524
- 试验地点
- 1
- 主要终点
- Change From Baseline in the Weekly Mean of the 24-Hour Average Pain Score at 8 Weeks
研究概览
简要总结
The study will test the hypothesis that, in patients with knee pain due to osteoarthritis (OA) who are taking nonsteroidal anti-inflammatory drugs (NSAIDs) but still have significant knee pain, duloxetine 60 to 120 milligrams (mg) daily for 10 weeks will provide additional reduction in pain.
详细描述
Duloxetine has been studied in pain due to osteoarthritis (OA) in 2 previous placebo controlled clinical trials. In clinical practice, when nonsteroidal anti-inflammatory drugs (NSAIDs) are ineffective in reducing pain due to OA, clinicians often add a second agent without discontinuing NSAIDs. In this study, we will investigate whether adding duloxetine to NSAIDs provides additional pain relief and functional improvement in patients with knee pain due to OA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Present with knee pain due to osteoarthritis (OA) based on OA clinical and radiographic diagnostic criteria.
- •Knee Pain for > 14 days of each month for the 3 months directly preceding study entry.
- •Taking nonsteroidal anti-inflammatory drugs (NSAIDs) for knee pain due to OA on most days in the 3 months immediately preceding study entry.
排除标准
- •History of intolerance or nonresponsiveness to an adequate trial of duloxetine used for any indication, in the opinion of the investigator.
- •Previous diagnosis of psychosis, bipolar disorder, or schizoaffective disorder.
- •Have major depressive disorder (MDD) as determined using depression module of the Mini International Neuropsychiatric Interview (MINI).
- •Judged clinically by the investigator to be at suicidal risk by examination or using the Columbia Suicide Severity Rating Scale (C-SSRS).
- •History of substance abuse or dependence within the past year, excluding nicotine and caffeine.
- •Positive urine drug screen for any substance of abuse or excluded medication.
- •Opioid dependent in the opinion of the investigator, taking opioids more than 3 days a week, or unwilling to discontinue opioids during the study period.
- •Known hypersensitivity to duloxetine or its inactive ingredients.
- •History of intolerance or hypersensitivity to NSAIDS, Cyclooxygenase (COX-2) inhibitors, or proton pump inhibitors.
- •History of peptic ulcer disease, bleeding disorder, gastrointestinal bleeding, or any abnormal bleeding.
- •Baseline hemoglobin measurement of <11 grams per deciliter (g/dL) for males, or <10 g/dL for females.
- •Serious or unstable cardiovascular, hepatic, renal, metabolic, respiratory, or hematologic illness, symptomatic peripheral vascular disease, or any other medical or psychiatric condition that would compromise participation or be likely to lead to hospitalization or a change in medication during the course of the study.
- •Uncorrected thyroid disease, uncontrolled narrow-angle glaucoma, uncontrolled or poorly controlled hypertension, or history of seizures.
- •Active liver injury (such as hepatitis) or any degree of hepatic insufficiency (Child-Pugh Class C).
- •Frequent falls that could result in hospitalization or could compromise response to treatment.
- •Confounding painful condition that may interfere with assessment of the index knee.
- •Chronic widespread pain affecting all four quadrants of the body, or diagnosis of fibromyalgia.
- •Received intra-articular hyaluronate (Synvisc), steroids, joint lavage, or other invasive therapies to the knee in the past 6 months.
- •Arthroscopy of the index knee within the past year or joint replacement of the index knee at anytime.
- •Diagnosis of inflammatory arthritis (that is, rheumatoid arthritis, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, etc.) or an autoimmune disorder (excluding inactive Hashimoto's thyroiditis).
- •Prior synovial fluid analysis showing a white blood cell count greater than or equal to 2000 cubic millimeters (mm^3) that is indicative of a diagnosis other than OA, or have a history of gout or pseudogout.
- •Radiographic evidence of end-stage (bone on bone) OA in either knee.
- •Knee replacement surgery planned within the next 6 months.
- •Nonambulatory or requiring the use of crutches, a walker, or more than 1 cane.
- •Body mass index (BMI) >40.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Duloxetine
Experimental
干预措施: Duloxetine (Drug)
结局指标
主要结局
Change From Baseline in the Weekly Mean of the 24-Hour Average Pain Score at 8 Weeks
时间窗: Baseline, 8 weeks (blinded endpoint)
The weekly mean 24-hour average pain score was calculated from the participant's daily 24-hour average pain ratings using an 11-point numeric rating scale, with scores from 0 (indicating "no pain") to 10 (indicating "the worst possible pain"). The Least Squares Mean estimates were adjusted for baseline, treatment, investigator (pooled), week, treatment\*week, and baseline\*week.
次要结局
- Patient Global Impression of Improvement (PGI-I) at 8 Weeks(8 weeks (blinded endpoint))
- Change From Baseline in the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) Pain, Stiffness, and Physical Function Subscale Scores at 8 Weeks(Baseline, 8 weeks (blinded endpoint))
- Change From Baseline in the Weekly Mean of the 24-Hour Night Pain and Worst Pain Scores at 8 Weeks(Baseline, 8 weeks (blinded endpoint))
- Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) Scores at 8 Weeks(Baseline, 8 weeks (blinded endpoint))
- Change From Baseline in the Clinical Global Impression of Severity (CGI-S) at 8 Weeks(Baseline, 8 weeks (blinded endpoint))
- Change From Baseline in the Patient Global Assessment of Illness (PGAI) at 8 Weeks(Baseline, 8 weeks (blinded endpoint))
- Change From Baseline in the Profile of Mood States-Brief Form (BPOMS) Total and Subscale Scores at 8 Weeks(Baseline, 8 weeks (blinded endpoint))
- Percentage of Participants Using Acetaminophen Weekly During the 10-Week Treatment Period(Baseline through 10 weeks (blinded endpoint))
- Percentage of Responders as Assessed by the Osteoarthritis Research Society International (OARSI) Response Criteria up to 8 Weeks(Up to 8 weeks (blinded endpoint))
- Percentage of Participants Who Achieved a 30 Percent or 50 Percent Reduction in the Weekly Mean of the 24-Hour Average Pain Score up to 8 Weeks(Up to 8 weeks (blinded endpoint))
- Percentage of Participants Who Achieved a 30 Percent or 50 Percent Reduction in the Brief Pain Inventory-Severity (BPI-S) Average Pain Score up to 8 Weeks(Up to 8 weeks (blinded endpoint))
- Percentage of Participants Who Discontinued Due to an Adverse Event During the 10-Week Treatment Period(Baseline through 10 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)Rheumatoid ArthritisNCT00132769Merck Sharp & Dohme LLC106
已完成
3 期
Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and PainDepressive Disorder, MajorNCT02232555Boehringer Ingelheim327
已完成
不适用
New Options for Treating Knee Osteoarthritis PainKnee OsteoarthritisNCT05541718University of Utah164
已完成
1 期
Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the KneeOsteoarthritisNCT00819572ESBATech AG27
已完成
4 期
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety DisorderIrritable Bowel SyndromeGeneralized Anxiety DisorderNCT00961298West Penn Allegheny Health System17